Menlo Therapeutics & Foamix Merger 2020 Dermatology Combination Presentation

Investor presentation for the proposed merger between Menlo Therapeutics and Foamix Pharmaceuticals to create a compelling dermatology combination. The combined company would leverage Foamix's FDA-approved topical minocycline, late-stage candidates, and proprietary Molecular Stabilizing Technology platform to address significant unmet needs in dermatology with indication-specific topical medicine innovation.